InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial

MLA

Mark P Saunders, et al. “InterAACT: A Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial of Cisplatin (CDDP) plus 5-Fluorouracil (5-FU) vs Carboplatin (C) plus Weekly Paclitaxel (P) in Patients (Pts) with Inoperable Locally Recurrent (ILR) or Metastatic Treatment Naïve Disease - An International Rare Cancers Initiative (IRCI) Trial.” Annals of Oncology, vol. 29, Oct. 2018, pp. viii715-viii716. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........f1c1ed833d8d5e0a5ce32b4172de5a83&authtype=sso&custid=ns315887.

APA

Mark P Saunders, David Cunningham, Amitesh Roy, Eva Segelov, Cathy Eng, John Bridgewater, Stephen Falk, David Sebag-Montefiore, Matthew T. Seymour, Annette Bryant, Rob Glynne-Jones, Richard Adams, Al B. Benson, Dirk Arnold, M. Gronlie Guren, F. Sclafani, John J. Welch, Clare Peckitt, Sheela Rao, & R. Muirhead. (2018). InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial. Annals of Oncology, 29, viii715-viii716.

Chicago

Mark P Saunders, David Cunningham, Amitesh Roy, Eva Segelov, Cathy Eng, John Bridgewater, Stephen Falk, et al. 2018. “InterAACT: A Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial of Cisplatin (CDDP) plus 5-Fluorouracil (5-FU) vs Carboplatin (C) plus Weekly Paclitaxel (P) in Patients (Pts) with Inoperable Locally Recurrent (ILR) or Metastatic Treatment Naïve Disease - An International Rare Cancers Initiative (IRCI) Trial.” Annals of Oncology 29 (October): viii715-viii716. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........f1c1ed833d8d5e0a5ce32b4172de5a83&authtype=sso&custid=ns315887.